Showing 1 - 10 of 43
; Innovation ; Pharmaceuticals ; Health care expenditure ; Cointegration …
Persistent link: https://www.econbiz.de/10003900852
; Innovation ; Pharmaceuticals ; Health care expenditure ; Cointegration …
Persistent link: https://www.econbiz.de/10003909500
Persistent link: https://www.econbiz.de/10011476376
This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals...
Persistent link: https://www.econbiz.de/10003900791
Persistent link: https://www.econbiz.de/10009753975
Persistent link: https://www.econbiz.de/10002010460
Persistent link: https://www.econbiz.de/10013378209
In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first presents the bounds testing procedure as a method to...
Persistent link: https://www.econbiz.de/10010315553
In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first presents the bounds testing procedure as a method to...
Persistent link: https://www.econbiz.de/10010285825
Studies on the effect of ageing on health care expenditures (HCE) have revealed the importance of controlling for time-to-death (TTD). These studies, however, are subject to possible endogeneity if HCE influences remaining life expectancy. This paper introduces a ten year observational period on...
Persistent link: https://www.econbiz.de/10003767521